TCGA-97-A4M2-01A-12R-A24X-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.300
- BILE_ACID_METABOLISM+0.280
- KRAS_SIGNALING_DN+0.280
- MYOGENESIS+0.280
- ALLOGRAFT_REJECTION+0.250
- INTERFERON_GAMMA_RESPONSE+0.220
- INFLAMMATORY_RESPONSE+0.210
- COMPLEMENT+0.190
- COAGULATION+0.180
- KRAS_SIGNALING_UP+0.140
Top 10 suppressed
- E2F_TARGETS-0.730
- MYC_TARGETS_V1-0.730
- G2M_CHECKPOINT-0.680
- MYC_TARGETS_V2-0.630
- UNFOLDED_PROTEIN_RESPONSE-0.590
- MTORC1_SIGNALING-0.560
- PROTEIN_SECRETION-0.530
- GLYCOLYSIS-0.520
- OXIDATIVE_PHOSPHORYLATION-0.520
- DNA_REPAIR-0.480
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-97-8552-01A-11R-2403-07 | — | cohortA1 | 0.914 |
| 2 | MDT-AP-2296 | Med | Medulloblastoma | 0.911 |
| 3 | TCGA-55-7728-01A-11R-2187-07 | — | cohortA1 | 0.910 |
| 4 | BS_DV86M0Y7 | pilocytic astrocytoma | — | 0.904 |
| 5 | TCGA-93-A4JO-01A-21R-A24X-07 | — | cohortA1 | 0.904 |
| 6 | TCGA-44-2657-01A-01R-1107-07 | — | cohortA1 | 0.903 |
| 7 | TCGA-55-8513-01A-11R-2403-07 | — | cohortA1 | 0.902 |
| 8 | TCGA-NJ-A55O-01A-11R-A262-07 | — | cohortA2 | 0.902 |
| 9 | TCGA-E9-A3Q9-01A-11R-A21T-07 | — | B | 0.901 |
| 10 | BS_94MT16N2 | pilocytic astrocytoma | — | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.220 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.210 | Idelalisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.060 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |